Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02775500 · ClinicalTrials.gov registry record
Apremilast Pregnancy Exposure Registry
A clinical trial of Psoriasis and Psoriatic Arthritis, sponsored by University of California, San Diego.
- Active
- Registry status
- 233
- Enrollment target
- 1
- Study location
NCT02775500 is a study of Psoriasis and Psoriatic Arthritis that is active but no longer recruiting, run by University of California, San Diego. The registered enrollment target is 233 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02775500, a study of Psoriasis and Psoriatic Arthritis, is active but no longer recruiting, sponsored by University of California, San Diego.
- ACTIVE NOT RECRUITING
- Registry status
- 233 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the Apremilast Pregnancy Exposure Registry is to monitor planned and unplanned pregnancies exposed to apremilast and to evaluate the safety of this medication relative to specified pregnancy outcomes, and to evaluate potential effects of prenatal apremilast exposure on infant health status through one year of age.
Conditions Studied
Interventions
- DRUG apremilast
Study Locations (1)
California
- University of California, San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2014-11 |
| Est. Completion | 2025-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02775500
The ClinicalTrials.gov registry entry for NCT02775500 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (52% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which apremilast is the first listed.
NCT02775500 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02775500 about?
NCT02775500 is a clinical study titled "Apremilast Pregnancy Exposure Registry". The purpose of the Apremilast Pregnancy Exposure Registry is to monitor planned and unplanned pregnancies exposed to apremilast and to evaluate the safety of this medication relative to specified pregnancy outcomes, and to evaluate potential effects of prenatal apremilast exposure on infant health s...
What is the current status of trial NCT02775500?
This trial is currently active not recruiting. The enrollment target is 233 participants. The study started on 2014-11. Estimated completion is 2025-07.
What conditions does trial NCT02775500 study?
This clinical trial studies the following conditions: Psoriasis, Psoriatic Arthritis.
What interventions are being tested in trial NCT02775500?
The interventions under investigation include: apremilast (DRUG).
Who is sponsoring clinical trial NCT02775500?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02775500 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
RECRUITING · NA
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.